메뉴 건너뛰기
Journal of Clinical Oncology
Volumn 29, Issue 13, 2011, Pages
Reply to P. Potemski
Author keywords

[No Author keywords available]
Indexed keywords

BEVACIZUMAB; CAPECITABINE; PLACEBO;
EID: 79955580459     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.34.1479     Document Type: Letter
Times cited : (5)
References (7)
  • 1
    • 79955581584 scopus 로고    scopus 로고
    • Is the postprogression survival time really not shortened in the bevacizumab-containing arms of phase III clinical trials?
    • Potemski P: Is the postprogression survival time really not shortened in the bevacizumab-containing arms of phase III clinical trials? J Clin Oncol 29:e384-e385, 2010
    • (2010) J Clin Oncol , vol.29
    • Potemski, P.1
  • 2
    • 79951983770 scopus 로고    scopus 로고
    • Disease course patterns after discontinuation of bevacizumab: Pooled analysis of randomized phase III trials
    • Miles D, Harbeck N, Escudier B, et al: Disease course patterns after discontinuation of bevacizumab: Pooled analysis of randomized phase III trials. J Clin Oncol 29:83-88, 2011
    • (2011) J Clin Oncol , vol.29 , pp. 83-88
    • Miles, D.1    Harbeck, N.2    Escudier, B.3
  • 3
    • 60649087564 scopus 로고    scopus 로고
    • Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis
    • Ebos JM, Lee CR, Cruz-Munoz W, et al: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15:232-239, 2009
    • (2009) Cancer Cell , vol.15 , pp. 232-239
    • Ebos, J.M.1    Lee, C.R.2    Cruz-Munoz, W.3
  • 4
    • 60649106195 scopus 로고    scopus 로고
    • Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis
    • Pàez-Ribes M, Allen E, Hudock J, et al: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15:220-231, 2009
    • (2009) Cancer Cell , vol.15 , pp. 220-231
    • Pàez-Ribes, M.1    Allen, E.2    Hudock, J.3
  • 5
    • 69449090120 scopus 로고    scopus 로고
    • Thresholds for therapies: Highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009
    • Goldhirsch A, Ingle JN, Gelber RD, et al: Thresholds for therapies: Highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20:1319-1329, 2009
    • (2009) Ann Oncol , vol.20 , pp. 1319-1329
    • Goldhirsch, A.1    Ingle, J.N.2    Gelber, R.D.3
  • 6
    • 76949108277 scopus 로고    scopus 로고
    • RIBBON-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer
    • abstr 42
    • Brufsky A, Bondarenko IN, Smirnov V, et al: RIBBON-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer. Cancer Res 69:495s, 2009 (suppl 3; abstr 42)
    • (2009) Cancer Res , vol.69 , Issue.SUPPL. 3
    • Brufsky, A.1    Bondarenko, I.N.2    Smirnov, V.3
  • 7
    • 77949321968 scopus 로고    scopus 로고
    • Progression-free survival as surrogate and as true end point: Insights from the breast and colorectal cancer literature
    • Saad ED, Katz A, Hoff PM, et al: Progression-free survival as surrogate and as true end point: Insights from the breast and colorectal cancer literature. Ann Oncol 21:7-12, 2010
    • (2010) Ann Oncol , vol.21 , pp. 7-12
    • Saad, E.D.1    Katz, A.2    Hoff, P.M.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.